WO2018093484A1 - Lasofoxifene treatment of er+ breast cancer - Google Patents

Lasofoxifene treatment of er+ breast cancer Download PDF

Info

Publication number
WO2018093484A1
WO2018093484A1 PCT/US2017/055970 US2017055970W WO2018093484A1 WO 2018093484 A1 WO2018093484 A1 WO 2018093484A1 US 2017055970 W US2017055970 W US 2017055970W WO 2018093484 A1 WO2018093484 A1 WO 2018093484A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
lasofoxifene
inhibitor
mutation
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/055970
Other languages
English (en)
French (fr)
Inventor
Kaitlyn Andreano
Ching-Yi Chang
Donald P. Mcdonnell
Stephanie L. GAILLARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES17791239T priority Critical patent/ES2909576T3/es
Priority to EP17791239.1A priority patent/EP3525774B1/en
Priority to KR1020247000452A priority patent/KR20240007720A/ko
Priority to KR1020237008605A priority patent/KR102531354B1/ko
Application filed by Duke University filed Critical Duke University
Priority to CA3040266A priority patent/CA3040266A1/en
Priority to SG11201903236SA priority patent/SG11201903236SA/en
Priority to MX2019004184A priority patent/MX387856B/es
Priority to EP21215433.0A priority patent/EP4035662A1/en
Priority to RU2019114079A priority patent/RU2019114079A/ru
Priority to NZ752443A priority patent/NZ752443A/en
Priority to JP2019540308A priority patent/JP6892151B2/ja
Priority to KR1020227037620A priority patent/KR102623130B1/ko
Priority to AU2017360365A priority patent/AU2017360365B2/en
Priority to DK17791239.1T priority patent/DK3525774T3/da
Priority to KR1020217023829A priority patent/KR102462433B1/ko
Priority to CN201780073528.3A priority patent/CN110099680B/zh
Priority to KR1020197013405A priority patent/KR102285453B1/ko
Priority to BR112019007254-3A priority patent/BR112019007254A2/pt
Priority to PL17791239T priority patent/PL3525774T3/pl
Priority to IL284875A priority patent/IL284875B/en
Publication of WO2018093484A1 publication Critical patent/WO2018093484A1/en
Priority to IL265938A priority patent/IL265938B/en
Anticipated expiration legal-status Critical
Priority to ZA2019/02454A priority patent/ZA201902454B/en
Priority to AU2022246480A priority patent/AU2022246480B2/en
Priority to AU2025200327A priority patent/AU2025200327A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • Estrogen receptor positive (ER + ) breast cancers are a group of breast cancers that express estrogen receptor a (ERa). Approximately 70% of breast cancers are ER + and are, therefore, treated with endocrine therapy. Endocrine therapy has led to significant improvement in outcome of women with ER + breast cancer by lowering the level of estrogen or blocking estrogen signaling. However, its effectiveness is limited by intrinsic and acquired endocrine resistance.
  • ESR1 Estrogen Receptor 1
  • a method of treating locally advanced or metastatic breast cancer in women comprises selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER + ) locally advanced or metastatic breast cancer, and administering to the selected patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • ER + estrogen receptor positive
  • the selected patient has previously been treated with one or more lines of endocrine therapy. In certain embodiments, the patient has previously been treated with a plurality of lines of endocrine therapy.
  • the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM).
  • SERM selective ER modulator
  • the SERM is tamoxifen, raloxifene, apeledoxifene, toremifene, or ospemifene.
  • the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD).
  • the SERD is fulvestrant, RAD1901, ARN-810 (GDC-0810), or AZD9496.
  • the endocrine therapy that the patient has previously been treated with is an aromatase inhibitor.
  • the aromatase inhibitor is exemestane (Aromasin®), letrozole (Femara®), or anastrozole (Arimidex®).
  • the patient has disease progression after endocrine therapy. In some embodiments, the patient is resistant to endocrine therapy.
  • the patient's cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
  • the patient has previously been determined to have at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
  • the method further comprises the earlier step of:
  • LBD ligand binding domain
  • ESR1 Estrogen Receptor 1
  • the at least one of gain of function missense mutation is in any one of amino acids D538, Y537, L536, P535, V534, S463, V392, or E380.
  • the at least one gain of function missense mutation is in the amino acid D538.
  • the mutation is D538G.
  • the at least one gain of function missense mutation is in the amino acid Y537.
  • the mutation is Y537S, Y537N, Y537C, or Y537Q. In some preferred embodiments, the mutation is Y537C.
  • the at least one gain of function missense mutation is in the amino acid L536.
  • the mutation is L536R or L536Q.
  • the at least one gain of function missense mutation is in the amino acid P535. In some embodiments, the mutation is P535H.
  • the at least one gain of function missense mutation is in the amino acid V534. In some embodiments, the mutation is V534E.
  • the at least one gain of function missense mutation is in the amino acid S463. In some embodiments, the mutation is S463P.
  • the at least one gain of function missense mutation is in the amino acid V392. In some embodiments, the mutation is V392I.
  • the at least one gain of function missense mutation is in the amino acid E380. In some embodiments, the mutation is E380Q. [0025] In some embodiments, the serum estradiol level of the patient is at least 0.35 ng/dL. In some embodiments, the serum estradiol level of the patient is about 0.30 ng/dL to about 0.35 ng/dL. In some embodiments, the serum estradiol level of the patient is about 0.25 ng/dL to about 0.30 ng/dL.
  • lasofoxifene is administered to the selected ER + locally advanced or metastatic breast cancer patient as lasofoxifene tartrate.
  • lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.
  • lasofoxifene is administered by oral administration.
  • lasofoxifene is administered at about 0.5 mg/day per os (p.o.) to about 10 mg/day per os.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os.
  • lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.
  • the method further comprises treating the patient with at least one additional endocrine therapy.
  • the patient is treated with the additional endocrine therapy at original doses.
  • the patient is treated with the additional endocrine therapy at doses higher than original doses.
  • the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene.
  • the additional endocrine therapy is treatment with a selective ER degrader (SERD).
  • the additional endocrine therapy is treatment with an aromatase inhibitor.
  • the method further comprises administering to the ER + locally advanced or metastatic breast cancer patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor.
  • mTOR mammalian target of rapamycin
  • the mTOR inhibitor is Everolimus.
  • the method further comprises administering to the patient an effective amount of phosphoinositide 3 -kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor.
  • PI3K phosphoinositide 3 -kinase
  • HSP90 heat shock protein 90
  • the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor.
  • HER2 inhibitor is trastuzumab (Herceptin®) or ado-trastuzumab emtansine (Kadcyla®).
  • the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor.
  • HDAC histone deacetylase
  • the HDAC inhibitor is vorinostat (Zolinza®), romidepsin (Istodax®), chidamide (Epidaza®), panobinostat (Farydak®), belinostat (Beleodaq®, PXD101), valproic acid (Depakote®, Depakene®, Stavzor®), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane.
  • Vorinostat Zaolinza®
  • the method further comprises administering to the patient an effective amount of a checkpoint inhibitor.
  • the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-L1 programmed death-ligand 1
  • CTLA-4 cytotoxic T- lymphocyte-associated protein 4
  • the PD-1 antibody is pembrolizumab (Keytruda®) or nivolumab (Opdivo®).
  • the CTLA-4 antibody is ipilimumab (Yervoy®).
  • the method further comprises administering to the patient an effective amount of cancer vaccine.
  • the patient is premenopausal.
  • the patient has locally advanced or metastatic ER+/HER2- breast cancer.
  • the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • the patient is perimenopausal.
  • the patient has locally advanced or metastatic ER+/HER2- breast cancer.
  • the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • the patient is postmenopausal.
  • the patient has locally advanced or metastatic ER+/HER2- breast cancer.
  • the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • a method of treating primary breast cancer in women comprises selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER + ) primary breast cancer, and administering to the selected patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • ER + estrogen receptor positive
  • lasofoxifene is administered to the selected ER + primary breast cancer patient as lasofoxifene tartrate.
  • lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.
  • lasofoxifene is administered by oral administration. In some of these
  • lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.
  • the method of treating ER + primary breast cancer further comprises treating the patient with at least one additional endocrine therapy.
  • the patient is treated with the additional endocrine therapy at original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene. In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD). In certain embodiments the additional endocrine therapy is treatment with an aromatase inhibitor.
  • SERM selective ER modulator
  • SESD selective ER degrader
  • the method further comprises administering to the ER + primary breast cancer patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor.
  • mTOR mammalian target of rapamycin
  • the mTOR inhibitor is Everolimus.
  • the method further comprises administering to the patient an effective amount of phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor.
  • PI3K phosphoinositide 3-kinase
  • HSP90 heat shock protein 90
  • the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor.
  • HER2 inhibitor is trastuzumab (Herceptin ® ) or ado-trastuzumab emtansine (Kadcyla ® ).
  • the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor.
  • HDAC histone deacetylase
  • the HDAC inhibitor is vorinostat (Zolinza ® ), romidepsin (Istodax ® ), chidamide (Epidaza ® ), panobinostat (Farydak ® ), belinostat (Beleodaq ® , PXD101), valproic acid
  • the method further comprises administering to the patient an effective amount of a checkpoint inhibitor.
  • the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
  • the PD-1 antibody is pembrolizumab (Keytruda ® ) or nivolumab (Opdivo ® ).
  • the CTLA-4 antibody is ipilimumab (Yervoy ® ).
  • the method further comprises administering to the patient an effective amount of cancer vaccine.
  • the patient is premenopausal. In certain embodiments, the patient is perimenopausal. In certain embodiments, the patient is postmenopausal.
  • a method of adjuvant therapy for estrogen receptor positive (ER+) breast cancer comprises administering to a patient who has received primary treatment for ER+ breast cancer an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof, in combination with an aromatase inhibitor.
  • lasofoxifene is administered continuously during the
  • lasofoxifene is administered cyclically during the administration of the aromatase inhibitor.
  • the dosing regimen of lasofoxifene is different from the dosing regimen of the aromatase inhibitor.
  • lasofoxifene is administered as lasofoxifene tartrate as adjuvant therapy in combination with an aromatase inhibitor.
  • the aromatase inhibitor is exemestane (Aromasin®), letrozole (Femara®), or anastrozole (Arimidex®).
  • lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.
  • lasofoxifene is administered by oral administration.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os.
  • lasofoxifene is
  • lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.
  • the method of adjuvant therapy for estrogen receptor positive (ER+) breast cancer further comprises treating the patient with at least one additional endocrine therapy.
  • the additional endocrine therapy is treatment with a selective ER degrader (SERD).
  • SESD selective ER degrader
  • the method of adjuvant therapy for estrogen receptor positive (ER+) breast cancer further comprises administering to the patient an effective amount of cyclin- dependent kinase 4/6 (CDK4/6) inhibitor.
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor.
  • mTOR mammalian target of rapamycin
  • the mTOR inhibitor is Everolimus.
  • the method further comprises administering to the patient an effective amount of phosphoinositide 3- kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor.
  • PI3K phosphoinositide 3- kinase
  • HSP90 heat shock protein 90
  • the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor.
  • HER2 inhibitor is trastuzumab (Herceptin®) or ado-trastuzumab emtansine (Kadcyla®).
  • the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor.
  • HDAC histone deacetylase
  • the HDAC inhibitor is vorinostat (Zolinza ® ), romidepsin (Istodax ® ), chidamide (Epidaza ® ), panobinostat (Farydak ® ), belinostat (Beleodaq ® , PXD101), valproic acid (Depakote ® , Depakene ® , Stavzor ® ), mocetinostat
  • the method further comprises administering to the patient an effective amount of a checkpoint inhibitor.
  • the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death- ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-L1 programmed death- ligand 1
  • CTLA-4 cytotoxic T-lymphocyte-associated protein 4
  • the PD-1 antibody is pembrolizumab (Keytruda ® ) or nivolumab (Opdivo ® ).
  • the CTLA-4 antibody is ipilimumab (Yervoy ® ).
  • the method further comprises administering to the patient an effective amount of cancer vaccine.
  • lasofoxifene is administered in an amount and on a schedule sufficient to improve bone mass. In some embodiments, lasofoxifene is administered in an amount and on a schedule sufficient to improve symptoms of WA.
  • the patient is premenopausal. In certain embodiments, the patient is perimenopausal. In certain embodiments, the patient is postmenopausal.
  • a method of treating cancers other than breast cancer in women comprises selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER + ) cancer, other than breast cancer, and has at least one gain of function mutations in the Estrogen Receptor 1 (ESR1) gene, and administering to the selected patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • the patient has been diagnosed with ER + ovarian cancer.
  • the patient has been diagnosed with ER + lung cancer.
  • lasofoxifene is administered to the selected patient with ER + cancer, other than breast cancer, as lasofoxifene tartrate.
  • lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.
  • lasofoxifene is administered by oral administration.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os.
  • lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.
  • the method of treating ER + cancer, other than breast cancer further comprises treating the patient with at least one additional endocrine therapy.
  • the patient is treated with the additional endocrine therapy at original doses.
  • the patient is treated with the additional endocrine therapy at doses higher than original doses.
  • the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene.
  • the additional endocrine therapy is treatment with a selective ER degrader (SERD).
  • SERM selective ER modulator
  • SESD selective ER degrader
  • the additional endocrine therapy is treatment with an aromatase inhibitor.
  • the method further comprises administering to the patient with ER + cancer, other than breast cancer, an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor.
  • mTOR mammalian target of rapamycin
  • the mTOR inhibitor is Everolimus.
  • the method further comprises administering to the patient an effective amount of phosphoinositide 3 -kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor.
  • PI3K phosphoinositide 3 -kinase
  • HSP90 heat shock protein 90
  • the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor.
  • HER2 inhibitor is trastuzumab (Herceptin®) or ado-trastuzumab emtansine (Kadcyla®).
  • the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor.
  • HDAC histone deacetylase
  • the HDAC inhibitor is vorinostat (Zolinza®), romidepsin (Istodax®), chidamide (Epidaza®), panobinostat (Farydak®), belinostat (Beleodaq®, PXD101), valproic acid (Depakote®, Depakene®, Stavzor®), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane.
  • Vorinostat Zaolinza®
  • the method further comprises administering to the patient an effective amount of a checkpoint inhibitor.
  • the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-L1 programmed death-ligand 1
  • CTLA-4 cytotoxic T- lymphocyte-associated protein 4
  • the PD-1 antibody is pembrolizumab (Keytruda®) or nivolumab (Opdivo®).
  • the CTLA-4 antibody is ipilimumab (Yervoy®).
  • the method further comprises administering to the patient an effective amount of cancer vaccine.
  • the patient is premenopausal. In certain embodiments, the patient is perimenopausal. In certain embodiments, the patient is postmenopausal.
  • a method of treating a female patient suffering from breast cancer who is at risk of acquiring a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene is presented.
  • the method comprises
  • a method of treating a female patient suffering from breast cancer who is at risk of acquiring resistance to endocrine therapy is presented.
  • the endocrine therapy is optionally (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).
  • the method comprises administering to the female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • the patient has primary breast cancer. In some of these
  • the primary breast cancer is locally advanced.
  • the patient has been treated with endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).
  • SERM selective ER modulator
  • SELD selective ER degrader
  • AI aromatase inhibitor
  • a method of treating a female patient suffering from estrogen receptor positive (ER+) primary breast cancer comprises administering to a female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • ER+ estrogen receptor positive
  • the patient is at risk of acquiring resistance to endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).
  • SERM selective ER modulator
  • SELD selective ER degrader
  • AI aromatase inhibitor
  • the primary breast cancer is locally advanced.
  • the patient has been treated with endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).
  • SERM selective ER modulator
  • SELD selective ER degrader
  • AI aromatase inhibitor
  • a method of treating a female patient suffering from estrogen receptor positive (ER+) locally advanced or metastatic breast cancer comprises administering to a female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • ER+ estrogen receptor positive
  • the selected patient has previously been treated with one or more lines of endocrine therapy. In certain embodiments, the patient has previously been treated with a plurality of lines of endocrine therapy.
  • the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM).
  • SERM selective ER modulator
  • the SERM is tamoxifen, raloxifene, apeledoxifene, toremifene, or ospemifene.
  • the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD).
  • SESD selective ER degrader
  • the SERD is fulvestrant, RAD1901, ARN-810 (GDC-0810), or AZD9496.
  • the endocrine therapy that the patient has previously been treated with is an aromatase inhibitor.
  • the aromatase inhibitor is exemestane (Aromasin®), letrozole (Femara®), or anastrozole (Arimidex®).
  • the patient has disease progression after endocrine therapy. In some embodiments, the patient is resistant to endocrine therapy.
  • the patient's cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
  • the patient has previously been determined to have at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
  • the method further comprises the earlier step of:
  • LBD ligand binding domain
  • ESR1 Estrogen Receptor 1
  • the at least one of gain of function missense mutation is in any one of amino acids D538, Y537, L536, P535, V534, S463, V392, or E380.
  • the at least one gain of function missense mutation is in the amino acid D538.
  • the mutation is D538G.
  • the at least one gain of function missense mutation is in the amino acid Y537.
  • the mutation is Y537S, Y537N, Y537C, or Y537Q. In some preferred embodiments, the mutation is Y537C.
  • the at least one gain of function missense mutation is in the amino acid L536.
  • the mutation is L536R or L536Q.
  • the at least one gain of function missense mutation is in the amino acid P535. In some embodiments, the mutation is P535H.
  • the at least one gain of function missense mutation is in the amino acid V534. In some embodiments, the mutation is V534E.
  • the at least one gain of function missense mutation is in the amino acid S463. In some embodiments, the mutation is S463P.
  • the at least one gain of function missense mutation is in the amino acid V392. In some embodiments, the mutation is V392I.
  • the at least one gain of function missense mutation is in the amino acid E380. In some embodiments, the mutation is E380Q.
  • lasofoxifene is administered to the selected ER + locally advanced or metastatic breast cancer patient as lasofoxifene tartrate.
  • lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.
  • lasofoxifene is administered by oral administration.
  • lasofoxifene is administered at about 0.5 mg/day per os (p.o.) to about 10 mg/day per os.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os.
  • lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.
  • the method further comprises treating the patient with at least one additional endocrine therapy.
  • the patient is treated with the additional endocrine therapy at original doses.
  • the patient is treated with the additional endocrine therapy at doses higher than original doses.
  • the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene.
  • the additional endocrine therapy is treatment with a selective ER degrader (SERD).
  • the additional endocrine therapy is treatment with an aromatase inhibitor.
  • the method further comprises administering to the ER + locally advanced or metastatic breast cancer patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor.
  • mTOR mammalian target of rapamycin
  • the mTOR inhibitor is Everolimus.
  • the method further comprises administering to the patient an effective amount of phosphoinositide 3 -kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor.
  • PI3K phosphoinositide 3 -kinase
  • HSP90 heat shock protein 90
  • the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor.
  • HER2 inhibitor is trastuzumab (Herceptin®) or ado-trastuzumab emtansine (Kadcyla®).
  • the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor.
  • HDAC histone deacetylase
  • the HDAC inhibitor is vorinostat (Zolinza®), romidepsin (Istodax®), chidamide (Epidaza®), panobinostat (Farydak®), belinostat (Beleodaq®, PXD101), valproic acid (Depakote®, Depakene®, Stavzor®), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane.
  • Vorinostat Zaolinza®
  • the method further comprises administering to the patient an effective amount of a checkpoint inhibitor.
  • the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
  • the PD-1 antibody is pembrolizumab (Keytruda ® ) or nivolumab (Opdivo ® ).
  • the CTLA-4 antibody is ipilimumab (Yervoy ® ).
  • the method further comprises administering to the patient an effective amount of cancer vaccine.
  • the patient is premenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • the patient is perimenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • the patient is postmenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • FIG. 1 A and FIG. IB show the effects of lasofoxifene on ESR1 ligand binding domain ("LBD") mutations in Caov2 ovarian carcinoma cells, with FIG. 1 A demonstrating that the mutant receptors are constitutively active and do not respond to 17- ⁇ estradiol (“E2”), and FIG. IB demonstrating that lasofoxifene inhibits the mutant receptor activity in a dose-response manner.
  • LBD ESR1 ligand binding domain
  • FIG. 2 A and FIG. 2B show the effects of lasofoxifene on ESR1 LBD mutations in SKBR3 breast adenocarcinoma cells, with FIG. 2A demonstrating that the mutant receptors are constitutively active and do not respond to 17- ⁇ estradiol (E2), and FIG. 2B demonstrating that lasofoxifene inhibits the mutant receptor activity in a dose-response manner.
  • E2 17- ⁇ estradiol
  • FIG. 3 A and FIG. 3B show the effects of lasofoxifene on ESR1 LBD mutations in stably transfected MCF7 breast cancer cells, with FIG. 3A demonstrating that lasofoxifene inhibits the Y537S mutant receptor activity with increasing dose titration, and FIG. 3B demonstrating that lasofoxifene inhibits the D538G mutant receptor activity with increasing dose titration.
  • Endocrine therapy is often used for treatment and prevention of ER + breast cancers.
  • Different types of endocrine therapy include selective ER modulators (SERMs), such as tamoxifen; selective ER degraders (SERDs), such as fulvestrant; and aromatase inhibitors (AIs).
  • SERMs selective ER modulators
  • SELDs selective ER degraders
  • AIs aromatase inhibitors
  • Estrogen Receptor 1 ESR1 gene mutations lead to the conformational change of the ERa protein towards a constitutively active state and result in ligand-independent activity that is relatively resistant to tamoxifen, fulvestrant, and estrogen deprivation. See Jeselsohn et ah, Clinical Cancer Research 20(7): 1757-1767 (2014).
  • Lasofoxifene is a nonsteroidal selective ER modulator (SERM). It has high binding affinity for the estrogen receptor and acts as a tissue-selective estrogen agonist or antagonist.
  • SERM selective ER modulator
  • PEARL Postmenopausal Evaluation and Risk- Reduction with Lasofoxifene
  • ER + estrogen receptor positive
  • methods of treating cancers in women comprising selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER + ) cancer.
  • the selected patient is treated with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • the patient has been diagnosed with ER + cancer by
  • the patient has been diagnosed with locally advanced or metastatic ER + breast cancer. In some embodiments, the patient has been diagnosed with ER + primary breast cancer. In some embodiments, the patient has been diagnosed with an ER + cancer other than breast cancer. In some of these embodiments, the patient has been diagnosed with ER + ovarian cancer. In some of these embodiments, the patient has been diagnosed with ER + lung cancer.
  • IHC immunohistochemistry
  • cells of the patient's cancer have acquired a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
  • LBD ligand binding domain
  • ESR1 Estrogen Receptor 1
  • the patient is at risk of acquiring resistance to endocrine therapy.
  • the patient is at risk of acquiring resistance to endocrine therapy due to the increased expression of estrogen receptor.
  • the patient is at risk of acquiring resistance to endocrine therapy due to the increased expression of co-activators of estrogen receptor.
  • the patient is at risk of acquiring resistance to endocrine therapy due to increased phosphorylation level and activity of estrogen receptor and its co-activators.
  • the patient is at risk of acquiring resistance to endocrine therapy due to change of tumor microenvironment and other host related factors.
  • the patient is at risk of acquiring resistance to endocrine therapy due to mutations in the Estrogen Receptor 1 (ESR1) gene.
  • ESR1 Estrogen Receptor 1
  • the endocrine therapy to which the patient is at risk of acquiring resistance is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor therapy (AI), or (iv) any combination of (i), (ii) and/or
  • the ER + cancer patient has previously been treated with one or more lines of endocrine therapy.
  • the patient has previously been treated with one line of endocrine therapy.
  • the patient has previously been treated with a plurality of lines of endocrine therapy.
  • the patient has previously been treated with two lines of endocrine therapy.
  • the patient has previously been treated with three lines of endocrine therapy.
  • the patient has previously been treated with four or more lines of endocrine therapy.
  • the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM).
  • SERM selective ER modulator
  • the selective ER modulator is selected from tamoxifen, raloxifene, apeledoxifene, toremifene, and ospemifene.
  • the selective ER modulator is tamoxifen.
  • the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD).
  • SESD selective ER degrader
  • the selective ER degrader binds to the estrogen receptor and leads to the proteasomal degradation of the receptor.
  • the selective ER degrader is selected from fulvestrant, RAD1901, ARN-810 (GDC-0810), and AZD9496. In certain embodiments, the selective ER degrader is fulvestrant.
  • the endocrine therapy with which the patient has previously been treated is an aromatase inhibitor (AI).
  • the aromatase inhibitor blocks the production of estrogen.
  • the aromatase inhibitor is selected from exemestane (Aromasin ® ), letrozole (Femara ® ), and anastrozole (Arimidex ® ).
  • the endocrine therapy that the patient has previously been treated with is ovarian suppression. In certain embodiments, ovarian suppression is achieved by oophorectomy. In certain embodiments, ovarian suppression is achieved by administration of a GnRH antagonist.
  • the patient's cancer has relapsed or progressed after the previous endocrine therapy treatment. In some embodiments, the patient's cancer has relapsed or progressed after tamoxifen treatment. In some embodiments, the patient's cancer has relapsed or progressed after fulvestrant treatment. In some embodiments, the patient's cancer has relapsed or progressed after aromatase inhibitor treatment. In some of these embodiments, the patient's cancer has relapsed or progressed after multiple lines of endocrine therapy treatment.
  • the ER + cancer patient has not been treated previously with endocrine therapy.
  • the patient is resistant to endocrine therapy other than lasofoxifene.
  • the patient has intrinsic endocrine resistance.
  • the patient has acquired endocrine resistance.
  • the patient is resistant to endocrine therapy due to the increased expression of estrogen receptor.
  • the patient is resistant to endocrine therapy due to the increased expression of co-activators of estrogen receptor.
  • the patient is resistant to endocrine therapy due to increased phosphorylation level and activity of estrogen receptor and its co-activators.
  • the patient is resistant to endocrine therapy due to change of tumor microenvironment and other host related factors.
  • the patient is resistant to endocrine therapy due to gene mutations in the Estrogen Receptor 1 (ESR1) gene.
  • the patient is resistant to clinical doses of one or more SERMs other than lasofoxifene. In some of these embodiments, the patient is resistant to clinical doses of tamoxifen. In various embodiments, the patient is resistant to clinical doses of one or more SERDs. In some of these embodiments, the patient is resistant to clinical doses of fulvestrant. In various embodiments, the patient is resistant to clinical doses of one or more aromatase inhibitors. In various embodiments, the patient is resistant to higher than clinical doses of one or more SERMs other than lasofoxifene. In some of these embodiments, the patient is resistant to higher than clinical doses of tamoxifen.
  • the patient is resistant to higher than clinical doses of one or more SERDs. In some of these embodiments, the patient is resistant to higher than clinical doses of fulvestrant. In various embodiments, the patient is resistant to higher than clinical doses of one or more aromatase inhibitors.
  • the ER + cancer patient has not been demonstrated to have endocrine resistance. In some of these embodiments, the patient has not been demonstrated to have endocrine resistance due to the limitations of the detection methods.
  • lasofoxifene is administered to the ER + cancer patient after completion of cancer treatment. In some of these embodiments, lasofoxifene is administered to the patient to treat occult micrometastasis.
  • the ER + cancer patient is premenopausal.
  • the patient is premenopausal and has locally advanced or metastatic ER + cancer.
  • the patient is premenopausal and has locally advanced or metastatic ER + breast cancer.
  • the ER + cancer patient is perimenopausal.
  • the patient is perimenopausal and has locally advanced or metastatic ER + cancer.
  • the patient is perimenopausal and has locally advanced or metastatic ER + breast cancer.
  • the ER + cancer patient is postmenopausal.
  • the patient is postmenopausal and has locally advanced or metastatic ER + cancer.
  • the patient is postmenopausal and has locally advanced or metastatic ER + breast cancer.
  • lasofoxifene is administered to a premenopausal woman with locally advanced or metastatic ER + /HER2 " breast cancer.
  • lasofoxifene is administered to a premenopausal woman with locally advanced or metastatic ER + /HER2 " breast cancer who has progressed while on her first hormonal treatment with a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • lasofoxifene is administered to a perimenopausal woman with locally advanced or metastatic ER + /HER2 " breast cancer.
  • lasofoxifene is administered to a perimenopausal woman with locally advanced or metastatic ER + /HER2 " breast cancer who has progressed while on her first hormonal treatment with a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • lasofoxifene is administered to a postmenopausal woman with locally advanced or metastatic ER + /HER2 " breast cancer.
  • lasofoxifene is administered to a postmenopausal woman with locally advanced or metastatic ER + /HER2 " breast cancer who has progressed while on her first hormonal treatment with on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.
  • AI non-steroid aromatase inhibitor
  • fulvestrant AI in combination with a CDK4/6 inhibitor
  • fulvestrant in combination with a CDK4/6 inhibitor
  • the patient has an ER + cancer, cells of which have at least one mutation in the Estrogen Receptor 1(ESR1) gene, which encodes the Estrogen Receptor a (ERa) protein.
  • the mutation leads to the ligand-independent activity of the estrogen receptor.
  • the mutation leads to enhanced ligand stimulated activity of estrogen receptor.
  • the mutation leads to resistance to endocrine therapy.
  • the mutation promotes tumor growth.
  • the mutation enhances metastatic activity of cancer.
  • the mutation enhances metastatic activity of ER + metastatic breast cancer.
  • the mutation arises from a rare and undetectable pre-existing clone.
  • the mutation is acquired de novo during the course of endocrine therapy treatment.
  • the mutation is acquired de novo during the course of endocrine therapy treatment of breast cancer.
  • the mutation is acquired de novo after multiple lines of endocrine therapy treatment.
  • the mutation is acquired de novo after multiple lines of endocrine therapy treatment of metastatic breast cancer.
  • the mutant clone expands to become a more dominant clone over the course of successive lines of endocrine therapy.
  • the mutation in the ESR1 gene is missense point mutation.
  • the mutation in the ESR1 gene is truncating mutation.
  • the mutation in the ESR1 gene is gene amplification. In some embodiments, the mutation in the ESR1 gene is genomic rearrangement.
  • the patient has an ER + cancer that has at least one gain of function missense mutation within the ligand binding domain (LBD) of the ESR1 gene.
  • LBD ligand binding domain
  • at least one of the mutations is in an amino acid selected from D538, Y537, L536, P535, V534, S463, V392, and E380. (The amino acids are numbered according to the ESR1 protein with the NCBI accession number NP 000116.2.)
  • the mutation increases the stability of the agonist
  • the mutation increases the binding of the estrogen receptor to its co-activators. In some of these embodiments, the mutation leads to hormone independent activity of estrogen receptor. In some of these embodiments, the mutation leads to resistance to tamoxifen, fulvestrant, and/or aromatase inhibitors.
  • the mutation is in the amino acid D538. In certain preferred embodiments, the mutation is D538G.
  • the mutation is in the amino acid Y537. In some of these embodiments, the mutation is Y537S, Y537N, Y537C, or Y537Q. In certain preferred embodiments, the mutation is Y537C.
  • the mutation is in the amino acid L536. In certain embodiments, the mutation is L536R or L536Q.
  • the mutation is in the amino acid P535. In certain embodiments, the mutation is P535H.
  • the mutation is in the amino acid V534. In certain embodiments, the mutation is V534E.
  • the mutation is in the amino acid S463. In certain embodiments, the mutation is S463P. [0119] In some embodiments, the mutation is in the amino acid V392. In certain embodiments, the mutation is V392I.
  • the mutation is in the amino acid E380. In certain embodiments, the mutation is E380Q.
  • the patient has been previously determined to have at least one mutation in the ESRl gene.
  • Some embodiments of the methods described herein further include the step of detecting the mutations in ESRl gene.
  • massively parallel next generation sequencing is used for detecting the estrogen receptor mutations in the patient's cancer.
  • the entire genome is sequenced.
  • selected gene panels of cancer-related genes are sequenced.
  • all coding exons within a given set of genes are sequenced.
  • known "hotspot" regions within a given set of genes are sequenced.
  • the inherent error rate of current next generation sequencing techniques is up to 1%, limiting the sensitivity and specificity of detection.
  • targeted sequencing is used for detecting the presence of the ESRl mutations. Although targeted sequencing allows deeper sequencing, it is also currently limited by the 1% error rate.
  • methods with reduced sequencing error rate are used.
  • Safe-Sequencing System (Safe-SeqS) is used, which tags each template molecule to allow for confident identification of rare variants. See kinde et ah, Proceedings of the National Academy of Sciences 108(23): 9530-9535 (2011).
  • ultrasensitive Duplex sequencing is used, which independently tags and sequences each of the two strands of a DNA duplex. See Schmitt et ah, Proceedings of the National Academy of Sciences 109(36): 14508- 14513 (2012).
  • digital droplet PCR is used, which emulsifies DNA in thousands to millions of droplets to encapsulate single DNA molecules, designed with mutant specific primers. See Vogelstein and Kinzler, Proceedings of the National Academy of Sciences 96(16): 2322-2326 (1999) and Huggett et al, Clinical Chemistry 61(1): 79-88 (2014).
  • the detection of the ESRl mutations takes place at the initial diagnosis. In some embodiments, the detection of the mutations takes place at the time of disease progression, relapse, or recurrence. In some embodiments, the detection of the mutations takes place at the time of disease progression. In some embodiments, the detection of the mutations takes place at the time when the disease is stable.
  • one or more tissue specimens are obtained for detection of the mutations.
  • the tissue specimen is a tumor biopsy.
  • the tissue specimen is a biopsy of metastases.
  • liquid biopsies are obtained for detection of the mutations.
  • the liquid biopsy is circulating tumor cells (CTCs).
  • the liquid biopsy is cell-free DNA from blood samples.
  • the ESR1 mutations are monitored by circulating tumor DNA (ctDNA) analysis.
  • the ctDNA analysis is performed throughout the course of treatment.
  • the ctDNA is extracted from patient blood samples.
  • the ctDNA is evaluated by digital PCR analysis of the ESR1 mutations.
  • the patient selected for treatment based on presence of ESR1 gene mutations is further selected based on serum estradiol level.
  • the serum estradiol level of the patient with the ER + cancer having an ESR1 gene mutation is at least 0.20 ng/dL, such as at least 0.25 ng/dL, at least 0.30 ng/dL, at least 0.35 ng/dL, at least 0.40 ng/dL, at least 0.45 ng/dL, at least 0.50 ng/dL, at least 0.55 ng/dL, at least 0.60 ng/dL, at least 0.65 ng/dL, at least 0.70 ng/dL, at least 0.75 ng/dL, at least 0.80 ng/dL, at least 0.85 ng/dL, at least 0.90 ng/dL, at least 0.95 ng/dL, or at least 1.0 ng/dL.
  • the serum estradiol level of the patient with the ESR1 gene mutation is about 0.20 ng/dL to about 1.0 ng/dL, such as about 0.20 ng/dL to about 0.25 ng/dL, about 0.25 ng/dL to about 0.30 ng/dL, about 0.30 ng/dL to about 0.35 ng/dL, about 0.35 ng/dL to about 0.40 ng/dL, about 0.40 ng/dL to about 0.45 ng/dL, about 0.45 ng/dL to about 0.50 ng/dL, about 0.50 ng/dL to about 0.55 ng/dL, about 0.55 ng/dL to about 0.60 ng/dL, about 0.60 ng/dL to about 0.65 ng/dL, about 0.65 ng/dL to about 0.70 ng/dL, about 0.70 ng/dL to about 0.75 ng/dL, about 0.75 ng/dL to about
  • lasofoxifene is administered to the patient as adjuvant treatment. In certain embodiments, lasofoxifene is administered to the patient as adjuvant treatment alone. In certain other embodiments, lasofoxifene is administered to the patient as adjuvant treatment in combination with other endocrine therapies. In some embodiments, lasofoxifene is administered to the patient after the primary treatment. In some of these embodiments, lasofoxifene is administered to the patient after surgical removal or debulking of the cancer.
  • lasofoxifene is administered to the patient as adjuvant therapy in combination with an aromatase inhibitor (AI).
  • AI aromatase inhibitor
  • the aromatase inhibitor is exemestane (Aromasin ® ), letrozole (Femara ® ), or anastrozole (Arimidex ® ).
  • the aromatase inhibitor predisposes the patient to bone-related toxic effects. In some embodiments, the aromatase inhibitor predisposes the patient to osteoporosis. In some embodiments, the aromatase inhibitor predisposes the patient to bone loss. In some embodiments, the aromatase inhibitor predisposes the patient to bone fractures. In some embodiments, the aromatase inhibitor predisposes the patient to bone pain.
  • the aromatase inhibitor predisposes the patient to vulvovaginal atrophy (WA).
  • lasofoxifene is administered continuously during the
  • lasofoxifene is administered cyclically during the administration of the aromatase inhibitor.
  • lasofoxifene and the aromatase inhibitor are administered together
  • lasofoxifene and the aromatase inhibitor are administered separately (sequentially).
  • the dosing regimen of lasofoxifene is different from the dosing regimen of the aromatase inhibitor.
  • the dosing quantity of lasofoxifene is different from the dosing quantity of the aromatase inhibitor.
  • the dosing schedule of lasofoxifene is different from the dosing schedule of the aromatase inhibitor.
  • the route of administration of lasofoxifene is different from the route of administration of the aromatase inhibitor.
  • the dosing regimen of lasofoxifene is the same as the dosing regimen of the aromatase inhibitor.
  • the dosing quantity of lasofoxifene is the same as the dosing quantity of the aromatase inhibitor.
  • the dosing schedule of lasofoxifene is the same as the dosing schedule of the aromatase inhibitor.
  • the route of administration of lasofoxifene is the same as the route of
  • lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for one year. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for two years. In some embodiments, lasofoxifene is administered as adjuvant therapy in
  • lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for four years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for five years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for six years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for seven years.
  • lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for eight years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for nine years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for ten years. In some other embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for more than ten years. In certain embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor until the patient's cancer progresses on therapy.
  • lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to increase the disease- free survival of the breast cancer patient. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to decrease the incidence of contralateral breast cancer. In some embodiments,
  • lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to prevent the recurrence or progression of the cancer.
  • the selected patient is treated with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • lasofoxifene is administered to the selected patient as lasofoxifene tartrate.
  • pharmaceutically acceptable salt refers to non-toxic pharmaceutically acceptable salts. See Gould, International Journal of Pharmaceutics 33: 201-217 (1986) and Berge et ah, Journal of Pharmaceutical Sciences 66(1): 1-19 (1977). Other salts well known to those in the art may, however, be used.
  • Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2- naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid.
  • Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine,
  • ethylenediamine, meglumine, procaine aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
  • Embodiments also include prodrugs of the compounds disclosed herein.
  • prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound.
  • the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
  • the processes for the preparation of the compounds as disclosed herein give rise to mixtures of stereoisomers
  • these isomers may be separated by conventional techniques such as preparative chromatography.
  • the compounds may be prepared in racemic form or as individual enantiomers or diastereomers by either stereospecific synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid.
  • the compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
  • the compounds may be resolved using a chiral HPLC column. It is to be understood that all stereoisomers, racemic mixtures, diastereomers, cis-trans isomers, and enantiomers thereof are encompassed by some embodiments.
  • Methods for treatment of estrogen receptor positive (ER + ) cancers include administering a therapeutically effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • the lasofoxifene, the pharmaceutically acceptable salt, or the prodrug of the invention can be formulated in pharmaceutical compositions.
  • the composition further comprises a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the precise nature of the carrier or other material can depend on the route of administration, e.g. oral, intravenous, transdermal, vaginal topical, or vaginal ring.
  • compositions for oral administration can be in tablet, capsule, powder or liquid form.
  • a tablet can include a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal oil, vegetable oil, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can also be included.
  • the lasofoxifene will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
  • Preservatives, stabilizers, buffers, antioxidants and/or other additives can be included, as required.
  • compositions for vaginal topical administration can be in the form of ointment, cream, gel or lotion.
  • the pharmaceutical compositions for vaginal topical can be in the form of ointment, cream, gel or lotion.
  • the pharmaceutical compositions for vaginal topical can be in the form of ointment, cream, gel or lotion.
  • administration often include water, alcohol, animal oil, vegetable oil, mineral oil or synthetic oil. Hydrocarbon (paraffin), wool fat, beeswax, macrogols, emulsifying wax or cetrimide can also be included.
  • Hydrocarbon paraffin
  • wool fat wool fat
  • beeswax wool fat
  • macrogols macrogols
  • emulsifying wax or cetrimide can also be included.
  • a composition can be administered alone or in combination with other treatments, either simultaneously or sequentially, dependent upon the condition to be treated.
  • treatment used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic, in terms of completely or partially preventing a disease, condition, or symptoms thereof, and/or may be therapeutic in terms of a partial or complete cure for a disease or condition and/or adverse effect, such as a symptom, attributable to the disease or condition.
  • Treatment covers any treatment of a disease or condition of a mammal, particularly a human, and includes: (a) preventing the disease or condition from occurring in a subject which may be predisposed to the disease or condition but has not yet been diagnosed as having it; (b) inhibiting the disease or condition (e.g., arresting its development); or (c) relieving the disease or condition (e.g., causing regression of the disease or condition, providing improvement in one or more symptoms).
  • the population of subjects treated by the method of the disease includes subjects suffering from the undesirable condition or disease, as well as subjects at risk for development of the condition or disease.
  • the term "effective amount” means a dose that produces the desired effect for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. See Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999).
  • lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.
  • lasofoxifene is administered to the patient by oral administration.
  • lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os, such as about 0.5 mg/day per os to about 5 mg/day per os, about 0.5 mg/day per os to about 5 mg/day per os, about 1 mg/day per os to about 5 mg/day per os, about 2 mg/day per os to about 5 mg/day per os, about 3 mg/day per os to about 5 mg/day per os, about 4 mg/day per os to about 5 mg/day per os, about 0.5 mg/day per os to about 4 mg/day per os, about 1 mg/day per os to about 4 mg/day per os, about 2 mg/day per os to about 4 mg/day per os, about 3 mg/day per os,
  • lasofoxifene is administered at about 0.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 1 mg/day per os. In some embodiments, lasofoxifene is administered at about 1.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 2 mg/day per os. In some embodiments, lasofoxifene is administered at about 2.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 3 mg/day per os. In some embodiments, lasofoxifene is administered at about 3.5 mg/day per os.
  • lasofoxifene is administered at about 4 mg/day per os. In some embodiments, lasofoxifene is administered at about 4.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 5 mg/day per os. In some embodiments, lasofoxifene is administered at about 6 mg/day per os. In some embodiments, lasofoxifene is administered at about 7 mg/day per os. In some embodiments, lasofoxifene is administered at about 8 mg/day per os. In some embodiments, lasofoxifene is administered at about 9 mg/day per os. In some embodiments, lasofoxifene is administered at about 10 mg/day per os. In some other embodiments, lasofoxifene is administered at more than 10 mg/day per os.
  • lasofoxifene when lasofoxifene is administered to patient whose cancer has not acquired endocrine resistance, lasofoxifene can be administered at less than 0.5 mg/day per os for prevention of endocrine resistance. In certain embodiments, when lasofoxifene is administered to cancer patient as adjuvant treatment, lasofoxifene can be administered at less than 0.5 mg/day per os for prevention of endocrine resistance.
  • lasofoxifene is administered once every day. In certain embodiments, lasofoxifene is administered once every two days. In certain embodiments, lasofoxifene is administered once every three days. In certain embodiments, lasofoxifene is administered once every four days. In certain embodiments, lasofoxifene is administered once every five days. In certain embodiments, lasofoxifene is administered once every six days. In certain embodiments, lasofoxifene is administered once every week. In certain embodiments, lasofoxifene is administered once every two weeks. In certain embodiments, lasofoxifene is administered once every three weeks. In certain embodiments, lasofoxifene is administered once every month.
  • lasofoxifene is administered to the patient by vaginal ring administration. In some of these embodiments, lasofoxifene is administered once every two weeks. In some of these embodiments, lasofoxifene is administered once every three weeks. In some of these embodiments, lasofoxifene is administered once every month. In some of these embodiments, lasofoxifene is administered once every two months. In some of these embodiments, lasofoxifene is administered once every three months. In some of these embodiments, lasofoxifene is administered once every four months.
  • lasofoxifene is administered to ER + cancer patient for one year. In some embodiments, lasofoxifene is administered to the patient for two years. In some embodiments, lasofoxifene is administered to the patient for three years. In some embodiments, lasofoxifene is administered to the patient for four years. In some embodiments, lasofoxifene is administered to the patient for five years. In some other embodiments, lasofoxifene is administered to the patient for more than five years. In certain embodiments, lasofoxifene is administered to the patient until the patient's cancer progresses on therapy.
  • lasofoxifene is administered either alone or in combination with other therapies. In certain embodiments, lasofoxifene is administered in combination with at least one other therapy. In some embodiments, lasofoxifene and other therapies are administered together (simultaneously). In some other embodiments, lasofoxifene and other therapies are administered at different times (sequentially).
  • the additional therapy that the patient is treated with is endocrine therapy.
  • the patient is treated with at least one line of additional endocrine therapy.
  • the patient is treated with one line of additional endocrine therapy.
  • the patient is treated with multiple lines of additional endocrine therapy.
  • the patient is treated with the additional endocrine therapy at the original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the patient is treated with the additional endocrine therapy at doses lower than original doses.
  • the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene.
  • SERM selective ER modulator
  • the selective ER modulator is selected from tamoxifen, raloxifene, apeledoxifene, toremifene, and ospermifene.
  • the selective ER modulator is tamoxifen.
  • the additional endocrine therapy is treatment with a selective ER degrader (SERD).
  • SESD selective ER degrader
  • the selective ER degrader is selected from fulvestrant, RAD1901, ARN-810 (GDC-0810), and AZD9496.
  • the selective ER degrader is fulvestrant.
  • the additional endocrine therapy is treatment with an aromatase inhibitor.
  • the aromatase inhibitor is selected from exemestane (Aromasin ® ), letrozole (Femara ® ), and anastrozole (Arimidex ® ).
  • the additional therapy is administration to the patient of an effective amount of a cell cycle inhibitor.
  • the additional therapy is administration of an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
  • the additional therapy is a CDK4/6 inhibitor selected from the group of palbociclib, abemaciclib, and ribociclib.
  • the additional therapy is administration to the patient of an inhibitor of a pathway that cross-talks with and activates the ER transcriptional activity.
  • the additional therapy is a mammalian target of rapamycin (mTOR) inhibitor.
  • the mTOR inhibitor is Everolimus.
  • lasofoxifene in combination with Everolimus is administered to a postmenopausal woman with locally advanced or metastatic breast cancer who has progressed on a non-steroidal AI and/or fulvestrant either as monotherapy or in combination with a CDK4/6 inhibitor.
  • the additional therapy is a phosphoinositide 3 -kinase (PI3K) inhibitor or a heat shock protein 90 (HSP90) inhibitor.
  • PI3K phosphoinositide 3 -kinase
  • HSP90 heat shock protein 90
  • the additional therapy is administration to the patient of an effective amount of a growth factor inhibitor.
  • the additional therapy is a human epidermal growth factor receptor 2 (HER2) inhibitor.
  • the HER2 inhibitor is trastuzumab (Herceptin ® ).
  • the HER2 inhibitor is ado- trastuzumab emtansine (Kadcyla ® ).
  • the additional therapy is administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor.
  • HDAC histone deacetylase
  • the HDAC inhibitor is vorinostat (Zolinza ® ), romidepsin (Istodax ® ), chidamide (Epidaza ® ), panobinostat (Farydak ® ), belinostat (Beleodaq ® , PXD101), valproic acid (Depakote ® , Depakene ® , Stavzor ® ), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, te
  • the HDAC inhibitor is entinostat (MS-275) with the proviso that the patient is not treated with a HER2 inhibitor.
  • the HDAC inhibitor is vorinostat (Zolinza ® ).
  • the HDAC inhibitor is romidepsin (Istodax ® ).
  • the additional therapy is administering to the patient an effective amount of a checkpoint inhibitor.
  • the checkpoint inhibitor is an antibody.
  • the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
  • the PD-1 antibody is pembrolizumab (Keytruda ® ) or nivolumab (Opdivo ® ).
  • the CTLA-4 antibody is ipilimumab (Yervoy ® ).
  • the additional therapy is administering to the patient an effective amount of cancer vaccine.
  • the additional therapy is administering to the patient an effective amount of denosumab.
  • the additional therapy is administering to the patient an effective amount of a serotonin-norepinephrine reuptake inhibitor (SNRI), a selective serotonin reuptake inhibitor (SSRI), or gabapentin.
  • SNRI serotonin-norepinephrine reuptake inhibitor
  • SSRI selective serotonin reuptake inhibitor
  • gabapentin gabapentin.
  • the SNRI is venlafaxine (Effexor ® ).
  • the method comprises administering an amount of lasofoxifene effective to increase the disease-free survival of the ER + cancer patient. In some embodiments, the method comprises administering lasofoxifene in an amount effective to reduce recurrence of ER + cancer. In some embodiments, the method comprises administering lasofoxifene in an amount effective to increase time to recurrence of ER + cancer. In some embodiments, the method comprises administering lasofoxifene in an amount effective to reduce metastasis of ER + cancer. In some embodiments, the method comprises administering lasofoxifene in an amount effective to increase duration of progression-free survival of the ER + cancer patient.
  • the method increases the disease-free survival of the ER + breast cancer patient. In certain embodiments, the method reduces recurrence of ER + breast cancer. In certain embodiments, the method increases time to recurrence of ER + breast cancer. In certain embodiments, the method reduces metastasis of ER + breast cancer to bone. In certain embodiments, the method reduces metastasis of ER + breast cancer to tissues other than bone. In certain embodiments, the method increases duration of progression-free survival of the ER + breast cancer patient.
  • the method increases the disease-free survival in ER + cancer patient with endocrine resistance. In some embodiments, the method reduces recurrence of cancer in patient with endocrine resistance. In some embodiments, the method increases time to recurrence of cancer in patient with endocrine resistance. In some embodiments, the method reduces metastasis of cancer in patient with endocrine resistance. In some embodiments, the method increases duration of progression-free survival in ER + cancer patient with endocrine resistance.
  • the method increases disease- free survival, reduces recurrence, increases time to recurrence, reduces metastasis, and/or increases duration of progression-free survival in patients with ER + locally advanced or metastatic breast cancer that has developed endocrine resistance.
  • the breast cancer has developed endocrine resistance by acquiring one or more of the ESRl mutations discussed herein.
  • the method reduces the selective pressure and prevents the expansion of the endocrine resistant clones in ER + locally advanced or metastatic breast cancer during treatment.
  • the method is effective to prevent fracture and bone loss in women who are concurrently being treated with one or more drugs causing or predisposing to osteoporosis.
  • the method is effective to decrease vaginal pH, increase vaginal lubrication, and/or improve vaginal cell maturation index in women who are concurrently being treated with one or more drugs causing or predisposing to vulvovaginal atrophy (WA).
  • WA vulvovaginal atrophy
  • the method reduces one or more symptoms of sexual dysfunction in women who are concurrently being treated with one or more drugs causing or predisposing to sexual dysfunction. [0177] In some embodiments, the method treats hot flashes in women who are concurrently being treated with one or more drugs causing or predisposing to hot flashes.
  • the method increases one or more quality of life measures selected from joint ache, urogenital symptoms, bone loss, and bone fractures.
  • a method of treating locally advanced or metastatic breast cancer in women comprising: a) selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER + ) locally advanced or metastatic breast cancer; and
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • HER2 inhibitor is trastuzumab (Herceptin ® ) or ado-trastuzumab emtansine (Kadcyla ® ).
  • HDAC histone deacetylase
  • HDAC inhibitor is vorinostat (Zolinza ® ), romidepsin (Istodax ® ), chidamide (Epidaza ® ), panobinostat (Farydak ® ), belinostat (Beleodaq ® , PXD101), valproic acid (Depakote ® , Depakene ® , Stavzor ® ), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilin
  • checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-Ll), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-Ll programmed death-ligand 1
  • CTLA-4 cytotoxic T-lymphocyte-associated protein 4
  • CTLA-4 antibody is ipilimumab (Yervoy®).
  • a method of treating primary breast cancer in women comprising:
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • HER2 inhibitor is trastuzumab (Herceptin®) or ado-trastuzumab emtansine (Kadcyla®).
  • HDAC inhibitor is vorinostat (Zolinza®), romidepsin (Istodax®), chidamide (Epidaza®), panobinostat (Farydak®), belinostat (Beleodaq®, PXD101), valproic acid (Depakote®, Depakene®, Stavzor®), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givmostat (ITF2357), quismostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefmostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane.
  • vorinostat Zaolinza®
  • checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-Ll), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-Ll programmed death-ligand 1
  • CTLA-4 cytotoxic T-lymphocyte-associated protein 4
  • nivolumab (Keytruda ® ) or nivolumab (Opdivo ® ).
  • a method of adjuvant therapy of estrogen receptor positive (ER + ) breast cancer comprising:
  • aromatase inhibitor is exemestane (Aromasin®), letrozole (Femara®), or anastrozole (Arimidex®).
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • PI3K phosphoinositide 3-kinase
  • HSP90 heat shock protein 90
  • HDAC histone deacetylase
  • HDAC inhibitor is vorinostat (Zolinza ® ), romidepsin (Istodax ® ), chidamide (Epidaza ® ), panobinostat (Farydak ® ), belinostat (Beleodaq ® , PXD101), valproic acid (Depakote ® , Depakene ® , Stavzor ® ), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (Zolinza ® ), rom
  • checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-Ll), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-Ll programmed death-ligand 1
  • CTL-4 cytotoxic T-lymphocyte-associated protein 4
  • a method of treating cancers other than breast cancer in women comprising:
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • PI3K phosphoinositide 3-kinase
  • HSP90 heat shock protein 90
  • HER2 human epidermal growth factor receptor 2
  • HDAC histone deacetylase
  • HDAC inhibitor is vorinostat (Zolinza®), romidepsin (Istodax®), chidamide (Epidaza®), panobinostat (Farydak®), belinostat (Beleodaq®, PXD101), valproic acid (Depakote®, Depakene®, Stavzor®), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetnn, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane
  • vorinostat Zaolinza®
  • checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-L1 programmed death-ligand 1
  • CTLA-4 cytotoxic T-lymphocyte-associated protein 4
  • CTLA-4 antibody is ipilimumab (Yervoy ® ).
  • a method of treating a female patient suffering from breast cancer who is at risk of acquiring a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESRl) gene comprising administering to the female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • LBD ligand binding domain
  • ESRl Estrogen Receptor 1
  • a method of treating a female patient suffering from breast cancer who is at risk of acquiring resistance to endocrine therapy optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii), comprising administering to the female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • SERM selective ER modulator
  • SESD selective ER degrader
  • AI aromatase inhibitor
  • any one of embodiments 177 to 180 wherein the patient has been treated with endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).
  • SERM selective ER modulator
  • SESD selective ER degrader
  • AI aromatase inhibitor
  • a method of treating a female patient suffering from estrogen receptor positive (ER + ) primary breast cancer comprising administering to a female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • ER + estrogen receptor positive
  • endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).
  • SERM selective ER modulator
  • SELD selective ER degrader
  • AI aromatase inhibitor
  • SERM selective ER modulator
  • SESD selective ER degrader
  • AI aromatase inhibitor
  • a method of treating a female patient suffering from estrogen receptor positive (ER + ) locally advanced or metastatic breast cancer comprising administering to a female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • ER + estrogen receptor positive
  • the method any one of embodiments 186 to 188, wherein the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD).
  • SESD selective ER degrader
  • CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib.
  • HDAC histone deacetylase
  • HDAC inhibitor is vorinostat (Zolinza ® ), romidepsin (Istodax ® ), chidamide (Epidaza ® ), panobinostat (Farydak ® ), belinostat (Beleodaq ® , PXD101), valproic acid (Depakote ® , Depakene ® , Stavzor ® ), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (Zolinza ® ), romide
  • checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • PD-L1 programmed death-ligand 1
  • CTLA-4 cytotoxic T-lymphocyte-associated protein 4
  • nivolumab (Keytruda ® ) or nivolumab (Opdivo ® ).
  • ExSite mutagenesis was performed using the corresponding primers as summarized in Table 1 below on a pENTR2B ERa WT construct using Pfu ultra taq polymerase.
  • the primers were PNK phosphorylated.
  • the products were digested with Dpnl at 37°C for lhr, followed by overnight ligation at 16°C.
  • Ligated products were transformed into DH5a bacterial cells and grown on kanamycin resistant plates.
  • the pENTR clones were verified by sequencing and then swapped into the pcDNA-DEST vector using the Gateway system (Invitrogen) for expression analysis.
  • Caov2 ovarian carcinoma cells were grown in RPMI-1640 media (Gibco) supplemented with 8% Fetal Bovine Serum (FBS), Sodium Pyruvate (NaPyr) and non-essential amino acids (NEAA) and passaged every 2-3 days.
  • SKBR3 breast adenocarcinoma cells were grown in DMEM media (Gibco) supplemented with 8% Fetal Bovine Serum (FBS), Sodium Pyruvate (NaPyr) and non-essential amino acids (NEAA) and passaged every 2-3 days.
  • Cells were switched into a phenol-red free RPMI-1640 media supplemented with 8% charcoal stripped fetal bovine serum (CFS), NaPyr, and NEAA one day before plating for experiment. Cells were then plated in 96-well plates for experiment in the phenol red-free media an additional day before transfection.
  • CFS charcoal stripped fetal bovine serum
  • NaPyr NaPyr
  • NEAA fetal bovine serum
  • Caov2 cells were co-transfected with the 7X-TK-ERE-TATA luciferase reporter gene (Nagel et ah, Endocrinology 142(11): 4721-4728 (2001)) and expression constructs for either wild-type or mutant receptors using Fugene transfection reagent (Promega).
  • SKBR3 cells were co-transfected with 3X-TK-ERE-TATA luciferase reporter gene in the same conditions.
  • pCMV- ⁇ -gal was used as a control for transfection efficiency and pcDNA was added for a final DNA concentration of 75ng per triplicate group. Cells were treated with indicated ligand five hours post transfection.
  • ERa expression constructs were engineered to express one of four different ESR1 LBD mutations, Y537S, Y537N, Y537C, and D538G, which are found in metastatic breast cancer patients. See Jeselsohn et al, Nature Reviews Clinical Oncology 12(10): 573-583 (2015);
  • the transcriptional IC90 value of lasofoxifene was also evaluated under the same conditions in Caov2 ovarian carcinoma cells and SKBR3 breast adenocarcinoma cells. See Maximov et al. , Current Clinical Pharmacolog 8(2): 135-155 (2013). The transcriptional IC90 value of lasofoxifene evaluated was compared to the Cmax of these compounds in blood at doses used in prior clinical trials and approved in Europe. See Assessment Report for Fablyn, 2009 (EMA). The calculation included Cmax of lasofoxifene at theoretical doses of 0.5mg and lmg.
  • the WT receptor was the most responsive to anti-estrogen treatment, with each of the mutants exhibiting reduced response to the inhibitory actions of lasofoxifene.
  • MCF7 estrogen receptor alpha positive (ER + ) breast cancer cells were engineered to stably express doxycycline (DOX)-inducible hemagglutinin (HA)-tagged full length ER with ligand binding domain mutations Y537S and D538G.
  • DOX doxycycline
  • HA hemagglutinin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
PCT/US2017/055970 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer Ceased WO2018093484A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
KR1020227037620A KR102623130B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020247000452A KR20240007720A (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020237008605A KR102531354B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
DK17791239.1T DK3525774T3 (da) 2016-10-11 2017-10-10 Lasofoxifen behandling af er+ brystcancer
CA3040266A CA3040266A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
SG11201903236SA SG11201903236SA (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
MX2019004184A MX387856B (es) 2016-10-11 2017-10-10 Tratamiento con lasofoxifeno del cáncer de mama.
EP21215433.0A EP4035662A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
RU2019114079A RU2019114079A (ru) 2016-10-11 2017-10-10 Лечение er+ рака молочной железы лазофоксифеном
NZ752443A NZ752443A (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
JP2019540308A JP6892151B2 (ja) 2016-10-11 2017-10-10 Ｅｒ＋乳がんのラソフォキシフェン処置
PL17791239T PL3525774T3 (pl) 2016-10-11 2017-10-10 Leczenie lazofoksyfenem raka piersi er+
AU2017360365A AU2017360365B2 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of ER+ breast cancer
ES17791239T ES2909576T3 (es) 2016-10-11 2017-10-10 Tratamiento con lasofoxifeno del cáncer de mama ER+
KR1020217023829A KR102462433B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
CN201780073528.3A CN110099680B (zh) 2016-10-11 2017-10-10 Er+乳腺癌的拉索昔芬治疗
KR1020197013405A KR102285453B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
BR112019007254-3A BR112019007254A2 (pt) 2016-10-11 2017-10-10 tratamento lasofoxifeno de câncer de mama er+
EP17791239.1A EP3525774B1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
IL284875A IL284875B (en) 2016-10-11 2017-10-10 Zofoxifene treatment for breast cancer
IL265938A IL265938B (en) 2016-10-11 2019-04-10 Zofoxifene treatment for +er breast cancer
ZA2019/02454A ZA201902454B (en) 2016-10-11 2019-04-17 Lasofoxifene treatment of er+ breast cancer
AU2022246480A AU2022246480B2 (en) 2016-10-11 2022-10-09 Lasofoxifene treatment of ER+ breast cancer
AU2025200327A AU2025200327A1 (en) 2016-10-11 2025-01-16 Lasofoxifene treatment of ER+ breast cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US62/406,859 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US62/457,759 2017-02-10
US201762502299P 2017-05-05 2017-05-05
US62/502,299 2017-05-05

Publications (1)

Publication Number Publication Date
WO2018093484A1 true WO2018093484A1 (en) 2018-05-24

Family

ID=60186386

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2017/055970 Ceased WO2018093484A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
PCT/US2017/055974 Ceased WO2018071440A1 (en) 2016-10-11 2017-10-10 Treatment of breast cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2017/055974 Ceased WO2018071440A1 (en) 2016-10-11 2017-10-10 Treatment of breast cancer

Country Status (20)

Country Link
US (8) US20190231718A1 (enExample)
EP (2) EP3525774B1 (enExample)
JP (4) JP6892151B2 (enExample)
KR (5) KR20240007720A (enExample)
CN (3) CN112353796A (enExample)
AU (3) AU2017360365B2 (enExample)
BR (1) BR112019007254A2 (enExample)
CA (1) CA3040266A1 (enExample)
DK (1) DK3525774T3 (enExample)
ES (1) ES2909576T3 (enExample)
IL (2) IL284875B (enExample)
MX (2) MX387856B (enExample)
NZ (2) NZ752443A (enExample)
PL (1) PL3525774T3 (enExample)
PT (1) PT3525774T (enExample)
RU (1) RU2019114079A (enExample)
SG (2) SG11201903236SA (enExample)
TW (4) TWI790672B (enExample)
WO (2) WO2018093484A1 (enExample)
ZA (1) ZA201902454B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
US10905659B2 (en) 2016-10-11 2021-02-02 Duke University Lasofoxifene treatment of breast cancer
US12023321B2 (en) 2021-11-18 2024-07-02 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
TW202410890A (zh) * 2022-05-25 2024-03-16 美商神莫尼克斯製藥公司 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療
WO2025075631A1 (en) 2023-10-06 2025-04-10 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of endocrine therapy resistant er+ cancer
WO2025099482A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Synergistic loratadine-raloxifene-sorafenib compositions for the treatment of hepatic cancer
WO2025122504A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025165887A1 (en) * 2024-01-30 2025-08-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations
CN119842900A (zh) * 2025-01-17 2025-04-18 厦门飞朔生物技术有限公司 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
WO1999065498A1 (en) 1998-06-19 1999-12-23 Senju Pharmaceutical Co., Ltd. Agents for relieving side effects of adrenal cortex hormone
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
AU2991301A (en) 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
CN100448487C (zh) 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
WO2002056903A2 (en) 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
BR0308758A (pt) 2002-03-28 2004-12-28 Pfizer Prod Inc Lasofoxifeno purificado e método para purificação de lasofoxifeno racêmico por recristalização
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
MX368189B (es) 2004-10-20 2019-09-23 Endorecherche Inc Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas.
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
MY161598A (en) 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
US9351964B2 (en) * 2009-05-27 2016-05-31 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
EP2606130B1 (en) 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
JP2014508782A (ja) 2011-03-11 2014-04-10 メリマック ファーマシューティカルズ インコーポレーティッド ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用
EP2709661A4 (en) 2011-05-18 2015-01-28 Merck Sharp & Dohme COMBINATIONS OF THERAPEUTIC ANTI-IGF1R
WO2013056178A2 (en) * 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
WO2015136017A1 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN104208069A (zh) 2014-05-08 2014-12-17 上海市计划生育科学研究所 双炔失碳酯组合物和疾病治疗方法
EP3215137A1 (en) 2014-11-07 2017-09-13 Lipoxen Technologies Limited Method for treatment of primary hormone resistant endometrial and breast cancers
US20180049999A1 (en) 2015-04-14 2018-02-22 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
BR112019007254A2 (pt) 2016-10-11 2019-07-02 Duke University tratamento lasofoxifeno de câncer de mama er+
US20190231743A1 (en) 2016-10-11 2019-08-01 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
US10624874B2 (en) 2017-01-10 2020-04-21 Zhejiang Jiachi Development Pharmaceuticals Ltd Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
CN118369116A (zh) 2021-10-05 2024-07-19 杜克大学 包含肿瘤免疫的小分子调节物的组合物及其使用方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
TW202410890A (zh) 2022-05-25 2024-03-16 美商神莫尼克斯製藥公司 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 - 19
CUMMINGS ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 326, no. 8, 2010, pages 686 - 696
GARDNER ET AL., J CLIN PHARMACOL, vol. 46, no. 1, 2006, pages 52 - 58
GOULD, INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 33, 1986, pages 201 - 217
H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
HUGGETT ET AL., CLINICAL CHEMISTRY, vol. 61, no. 1, 2014, pages 79 - 88
JESELSOHN ET AL., CLINICAL CANCER RESEARCH, vol. 20, no. 7, 2014, pages 1757 - 1767
JESELSOHN ET AL., NATURE REVIEWS CLINICAL ONCOLOGY, vol. 12, no. 10, 2015, pages 573 - 583
JESELSOHN, CLINICAL CANCER RESEARCH, vol. 20, no. 7, 2014, pages 1757 - 1767
JESELSOHN, NATURE REVIEWS CLINICAL ONCOLOGY, vol. 12, no. 10, 2015, pages 573 - 583
KINDE ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 23, 2011, pages 9530 - 9535
LACROIX A ET AL.: "Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women", JNCI, 17 November 2010 (2010-11-17), pages 1706 - 1715, XP055438152, Retrieved from the Internet <URL:https://academic.oup.com/jnci/article-pdf/102/22/1706/7671945/djq415.pdf> [retrieved on 20180104], DOI: 10.1093/jnci/djq415 *
LACROIX, JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 102, no. 22, 2010, pages 1706 - 1715
LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999
MAXIMOV ET AL., CURRENT CLINICAL PHARMACOLOGY, vol. 8, no. 2, 2013, pages 135 - 155
NAGEL ET AL., ENDOCRINOLOGY, vol. 142, no. 11, 2001, pages 4721 - 4728
NORRIS ET AL., JBIOL CHEM, vol. 270, no. 39, 1995, pages 22777 - 22782
ROBINSON ET AL., NATURE GENETICS, vol. 45, no. 12, 2013, pages 1446 - 1451
SCHMITT ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 36, 2012, pages 14508 - 14513
SHELLY W ET AL: "Selective estrogen receptor modulators: An update on recent clinical findings", OBSTETRICAL AND GYNECOLOGICAL SURVEY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 63, no. 3, 29 February 2008 (2008-02-29), pages 163 - 181, XP009502604, ISSN: 0029-7828, DOI: 10.1097/OGX.0B013E31816400D7 *
THOMAS; GUSTAFSSON, TRENDS IN ENDOCRINOLOGY AND METABOLISM, vol. 26, no. 9, 2015, pages 467 - 476
TOY ET AL., NATURE GENETICS, vol. 45, no. 12, 2013, pages 1439 - 1445
TOY, NATURE GENETICS, vol. 45, no. 12, 2013, pages 1439 - 1445
VOGELSTEIN; KINZLER, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 96, no. 16, 1999, pages 2322 - 2326

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905659B2 (en) 2016-10-11 2021-02-02 Duke University Lasofoxifene treatment of breast cancer
US11980597B2 (en) 2016-10-11 2024-05-14 Duke University Lasofoxifene treatment of breast cancer
US12414924B2 (en) 2016-10-11 2025-09-16 Duke University Lasofoxifene treatment of breast cancer
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
EP3773524A4 (en) * 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
US11974983B2 (en) 2018-04-10 2024-05-07 Duke University Lasofoxifene treatment of breast cancer
US12023321B2 (en) 2021-11-18 2024-07-02 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+cancer
US12433866B2 (en) 2021-11-18 2025-10-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+ cancer

Also Published As

Publication number Publication date
JP2019529581A (ja) 2019-10-17
US11980597B2 (en) 2024-05-14
TWI836808B (zh) 2024-03-21
PT3525774T (pt) 2022-03-30
KR102285453B1 (ko) 2021-08-05
KR20210096316A (ko) 2021-08-04
BR112019007254A2 (pt) 2019-07-02
CN112353796A (zh) 2021-02-12
IL265938A (en) 2019-05-30
US20190231718A1 (en) 2019-08-01
US20210361596A1 (en) 2021-11-25
EP4035662A1 (en) 2022-08-03
US20180221335A1 (en) 2018-08-09
PL3525774T3 (pl) 2022-04-25
CN110099680B (zh) 2021-02-05
MX387856B (es) 2025-03-19
KR102462433B1 (ko) 2022-11-03
ZA201902454B (en) 2022-09-28
TWI896001B (zh) 2025-09-01
SG11201903236SA (en) 2019-05-30
TWI790672B (zh) 2023-01-21
MX2021013911A (es) 2022-01-18
US20190151286A1 (en) 2019-05-23
NZ793063A (en) 2025-09-26
TWI729227B (zh) 2021-06-01
KR20190092377A (ko) 2019-08-07
IL284875B (en) 2022-07-01
EP3525774B1 (en) 2021-12-29
EP3525774A1 (en) 2019-08-21
JP6892151B2 (ja) 2021-06-23
RU2019114079A (ru) 2020-11-13
TW202137980A (zh) 2021-10-16
JP2024026527A (ja) 2024-02-28
KR20230042390A (ko) 2023-03-28
TW202446367A (zh) 2024-12-01
ES2909576T3 (es) 2022-05-09
JP7418052B2 (ja) 2024-01-19
AU2025200327A1 (en) 2025-02-06
JP7247241B2 (ja) 2023-03-28
TW202313005A (zh) 2023-04-01
CA3040266A1 (en) 2018-05-24
TW201817422A (zh) 2018-05-16
JP7774896B2 (ja) 2025-11-25
KR102531354B1 (ko) 2023-05-11
CN112933082A (zh) 2021-06-11
CN110099680A (zh) 2019-08-06
IL265938B (en) 2021-08-31
KR20240007720A (ko) 2024-01-16
SG10201913951YA (en) 2020-03-30
KR20220151017A (ko) 2022-11-11
MX2019004184A (es) 2019-09-27
US20250064757A1 (en) 2025-02-27
RU2019114079A3 (enExample) 2021-07-23
NZ752443A (en) 2022-11-25
WO2018071440A1 (en) 2018-04-19
DK3525774T3 (da) 2022-03-14
AU2017360365A1 (en) 2019-05-02
JP2021073316A (ja) 2021-05-13
AU2022246480A1 (en) 2022-12-08
US10905659B2 (en) 2021-02-02
JP2023033415A (ja) 2023-03-10
US20240366534A1 (en) 2024-11-07
US12414924B2 (en) 2025-09-16
US10258604B2 (en) 2019-04-16
AU2017360365B2 (en) 2022-08-04
US20230233490A1 (en) 2023-07-27
IL284875A (en) 2021-08-31
US20180098963A1 (en) 2018-04-12
KR102623130B1 (ko) 2024-01-10
AU2022246480B2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
US12414924B2 (en) Lasofoxifene treatment of breast cancer
US11974983B2 (en) Lasofoxifene treatment of breast cancer
HK40077706A (en) Lasofoxifene treatment of er+ breast cancer
HK40005311B (en) Lasofoxifene treatment of er+ breast cancer
HK40005311A (en) Lasofoxifene treatment of er+ breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17791239

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019540308

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3040266

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019007254

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017360365

Country of ref document: AU

Date of ref document: 20171010

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197013405

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017791239

Country of ref document: EP

Effective date: 20190513

ENP Entry into the national phase

Ref document number: 112019007254

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190410